Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Genmab ( (GMAB) ).
On March 23, 2026, Genmab A/S filed a Form 6-K with the U.S. Securities and Exchange Commission, publishing an updated English translation of its Articles of Association dated March 19, 2026. The filing, signed by Executive Vice President and CFO Anthony Pagano, formally incorporates these governance changes into Genmab’s U.S. disclosure record and its existing registration statements.
The updated Articles clarify Genmab’s share capital structure at DKK 64,250,721 and extend the board’s authority to issue new shares, warrants, and convertible debt instruments within defined limits through 2029 and 2030. These authorizations enhance Genmab’s financial flexibility for capital raising and employee incentive programs, potentially affecting future dilution while reinforcing its governance framework for investors and other stakeholders.
The most recent analyst rating on (GMAB) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.
The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is a Denmark-based biotechnology company focused on medical research, as well as the production and sale of related products. Headquartered in Copenhagen, the company operates internationally in the biopharmaceutical sector, developing innovative therapies and leveraging equity and debt instruments to support its growth and employee incentives.
Average Trading Volume: 1,721,113
Technical Sentiment Signal: Sell
Current Market Cap: $15.6B
See more insights into GMAB stock on TipRanks’ Stock Analysis page.